|
gptkbp:instanceOf
|
antifungal medication
liposomal formulation
|
|
gptkbp:activeIngredient
|
gptkb:amphotericin_B
|
|
gptkbp:advantageOverConventional
|
improved tolerability
reduced nephrotoxicity
|
|
gptkbp:approvedBy
|
gptkb:FDA
1997
|
|
gptkbp:ATCCode
|
gptkb:J02AA01
|
|
gptkbp:brand
|
gptkb:AmBisome
|
|
gptkbp:CASNumber
|
1397-89-3 (amphotericin B)
|
|
gptkbp:color
|
yellow
|
|
gptkbp:contraindication
|
hypersensitivity to amphotericin B
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:form
|
lyophilized powder for injection
liposome-encapsulated
|
|
gptkbp:halfLife
|
7-15 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
liposomal amphotericin B
|
|
gptkbp:indication
|
gptkb:histoplasmosis
gptkb:mucormycosis
candidiasis
aspergillosis
cryptococcal meningitis
neutropenic fever
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to ergosterol in fungal cell membrane
forms pores in fungal cell membrane
|
|
gptkbp:molecularWeight
|
924.08 g/mol (amphotericin B)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:riskOfInfusionReaction
|
lower than conventional amphotericin B
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
fever
nausea
vomiting
chills
hypokalemia
nephrotoxicity
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:usedFor
|
treatment of fungal infections
treatment of leishmaniasis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:AmBisome
gptkb:Amphotericin_B
|
|
gptkbp:bfsLayer
|
7
|